Juno, Kite Stand By Their Products As Novartis's Shift Renews CAR-T Concerns

Novartis's consolidation of its cell and gene therapy division into its corporate R&D operation has other leading CAR-T developers defending their therapeutic candidates against technical and manufacturing doubts.